Taysha Gene Therapies, Inc. (TSHA) NASDAQ

5.69

-0.28(-4.69%)

Updated at June 02 04:00PM

Currency In USD

Taysha Gene Therapies, Inc.

Address

3000 Pegasus Park Drive

Dallas, TX 75247

United States of America (the)

Phone

214 612 0000

Sector

Healthcare

Industry

Biotechnology

Employees

73

First IPO Date

September 24, 2020

Key Executives

NameTitlePayYear Born
Sean NolanChief Executive Officer & Chairman1.19M1968
Kamran AlamChief Financial Officer & Corporate Secretary741,9041978
Sukumar NagendranPresident, Head of Research & Development and Director1.04M1967
Steven GrayChief Scientific Advisor of UT Southwestern Gene Therapy Program0N/A
Hayleigh CollinsDirector of Corporate Communications & Investor Relations0N/A
David McNinchChief Commercial Officer01969
Frederick PorterChief of Staff & Technical Operations Officer0N/A
Sean McAuliffeChief Business Officer0N/A
Berge MinassianChief Medical Advisor of UT Southwestern Gene Therapy Program0N/A
Emily McGinnisChief Patient & External Affairs Officer0N/A
Rumana Haque-AhmedChief Regulatory Officer0N/A
Tracy PorterChief People Officer0N/A

Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.